Pfizer (NY:<a title="Quote for Pfizer" href="https://business.thepilotnews.com/thepilotnews/quote?Symbol=NY%3APFE">PFE )

These companies are committed to rewarding shareholders.

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

Today 6:25 EDT

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

Today 0:37 EDT

CoreWeave vs. D-Wave Quantum: Is the AI Giant or the Quantum Computer Upstart the Better Stock Investment? ↗

September 21, 2026

Both are high-growth bets on unproven cutting-edge technologies.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Topics Artificial Intelligence

1 Mid-Cap Stock with Exciting Potential and 2 We Turn Down

September 21, 2026

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock? ↗

September 20, 2026

Pfizer's rebound is well underway.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Topics Intellectual Property World Trade

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

Pfizer has a history of developing treatments that generate billions in sales.

Topics Intellectual Property

Is Pfizer an Excellent Dividend Stock to Buy? ↗

September 19, 2026

They have a knack for increasing their dividends even when facing challenges.

3 Dividend Stocks to Buy and Hold for 10 Years ↗

September 18, 2026

I'd buy Energy Transfer and Verizon stocks, and avoid Pfizer.

Topics Intellectual Property

2 High-Yield Dividend Stocks to Buy and 1 to Avoid ↗

September 18, 2026

Income investors shouldn't be too worried about the pharma giant cutting its dividend.

Topics Artificial Intelligence Intellectual Property

Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive. ↗

September 17, 2026

The company is still looking to bounce back after the beating it took in recent years.

Topics Earnings Intellectual Property

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Topics Economy

1 Stock Under $50 to Target This Week and 2 That Underwhelm

September 16, 2026

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

September 15, 2026

Via Chartmill

IP Group H1 Earnings Call Highlights ↗

September 15, 2026

IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio...

Analysts think Alnylam could rebound strongly over the next 12 months.

Topics Earnings Initial Public Offering

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining...

Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗

September 14, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Topics Intellectual Property World Trade

3 Healthcare Stocks That Fall Short

September 14, 2026

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

How Concerned Should Income Investors Be About Pfizer's Dividend? ↗

September 12, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...

Topics Intellectual Property

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗

September 12, 2026

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo...

Topics ETFs

1 Oversold Stock Ready to Bounce Back and 2 Facing Challenges

September 11, 2026

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with...

Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot ↗

September 10, 2026

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Why Pfizer Stock Was so Healthy in August ↗

September 08, 2026

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Topics Intellectual Property

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗

September 08, 2026

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗

Topics Intellectual Property

September 07, 2026

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

This Is What I'd Do With Pfizer Stock Right Now ↗

September 07, 2026

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 04, 2026

After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime...

Topics Intellectual Property

3 Things You Need to Know If You Buy Pfizer Stock Today ↗

September 03, 2026

Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.

Topics Intellectual Property

Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion ↗

September 03, 2026

Via Benzinga

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

The company is coming back into the spotlight thanks to recent developments.